Extreme sensitivity to Yondelis® (Trabectedin, ET‐743) in low passaged sarcoma cell lines correlates with mutated p53

@article{Moneo2007ExtremeST,
  title={Extreme sensitivity to Yondelis{\textregistered} (Trabectedin, ET‐743) in low passaged sarcoma cell lines correlates with mutated p53},
  author={V. Moneo and Beatriz G. Serelde and J. Fominaya and J. Leal and C. Blanco-Aparicio and L. Romero and M. S{\'a}nchez-Beato and J. Cigudosa and J. Tercero and M. Piris and J. Jimeno and A. Carnero},
  journal={Journal of Cellular Biochemistry},
  year={2007},
  volume={100}
}
Yondelis® (Trabectedin, ET‐743) is a marine anticancer agent currently in Phase II/III development in patients with advanced pretreated soft tissue sarcoma. In the present study, we generated a panel of low passaged tumor cell lines from samples explanted from chemonaive sarcoma patients with different tumor types. We assessed in vitro sensitivity/resistance to Trabectedin and doxorubicin in a panel of sarcoma cell lines and examined the correlation between molecular alterations in DNA repair… Expand
In vitro radiosensitisation by trabectedin in human cancer cell lines.
Levels of p27kip1 determine Aplidin sensitivity
Levels of active tyrosine kinase receptor determine the tumor response to Zalypsis
...
1
2
3
4
...

References

SHOWING 1-10 OF 53 REFERENCES
Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naïve patients
In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients.
Unique pattern of ET‐743 activity in different cellular systems with defined deficiencies in DNA‐repair pathways
Characterization of the A673 cell line (Ewing tumor) by molecular cytogenetic techniques.
Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.
  • C. Sessa, F. de Braud, +10 authors N. Colombo
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
...
1
2
3
4
5
...